Nivolumab shows signs of superior response rate compared to standard chemotherapy in advanced melanoma

Monday, September 29, 2014 - 09:51 in Health & Medicine

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net